Cancer combo trial halted early: what happened?
Disease control
Terminated
This early-stage trial tested a new drug, azenosertib, combined with two standard cancer drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal was to find a safe dose and see if the combination shrank tumors. Only 7 people took pa…
Phase: PHASE1 • Sponsor: Filipa Lynce, MD • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC